advertisement
3.8 Pharmacology (65)
Showing records 1 to 25
Display all abstracts in classification 3.8 Pharmacology
Search within classification 3.8 Pharmacology94852 Neuroprotection in Glaucoma: NAD/NADH Redox State as a Potential Biomarker and Therapeutic Target
Petriti B
Cells 2021; 10:
94240 ATP and Adenosine in the Retina and Retinal Diseases
Ye SS
Frontiers in pharmacology 2021; 12: 654445
94406 Carotenoids in the Management of Glaucoma: A Systematic Review of the Evidence
Lem DW
Nutrients 2021; 13:
94764 Advances in the discovery of novel agents for the treatment of glaucoma
Mincione F
Expert Opinion on Drug Discovery 2021; 16: 1209-1225
95416 Agonist of growth hormone-releasing hormone enhances retinal ganglion cell protection induced by macrophages after optic nerve injury
Cen LP
Proceedings of the National Academy of Sciences of the United States of America 2021; 118:
94829 Tackling retinal ganglion cell apoptosis in glaucoma: role of adenosine receptors
Agarwal P
Expert Opinion on Therapeutic Targets 2021; 25: 585-596
94314 Agonistic autoantibodies against ß2-adrenergic receptor influence retinal microcirculation in glaucoma suspects and patients
Hohberger B
PLoS ONE 2021; 16: e0249202
94984 Nitric Oxide Interaction with the Eye
Erdinest N
Vision (Basel, Switzerland) 2021; 5:
94673 Stimulation of α7 nAChR leads to regeneration of damaged neurons in adult mammalian retinal disease models
Webster SE
Experimental Eye Research 2021; 210: 108717
94268 Adenosine: The common target between cancer immunotherapy and glaucoma in the eye
Hallaj S
Life Sciences 2021; 282: 119796
94380 Decorin-An Antagonist of TGF-β in Astrocytes of the Optic Nerve
Schneider M
International journal of molecular sciences 2021; 22:
94303 Prostanoid receptor agonists for glaucoma treatment
Aihara M
Japanese Journal of Ophthalmology 2021; 65: 581-590
94984 Nitric Oxide Interaction with the Eye
London N
Vision (Basel, Switzerland) 2021; 5:
94314 Agonistic autoantibodies against ß2-adrenergic receptor influence retinal microcirculation in glaucoma suspects and patients
Hosari S
PLoS ONE 2021; 16: e0249202
94268 Adenosine: The common target between cancer immunotherapy and glaucoma in the eye
Mirza-Aghazadeh-Attari M
Life Sciences 2021; 282: 119796
94852 Neuroprotection in Glaucoma: NAD/NADH Redox State as a Potential Biomarker and Therapeutic Target
Williams PA
Cells 2021; 10:
94829 Tackling retinal ganglion cell apoptosis in glaucoma: role of adenosine receptors
Agarwal R
Expert Opinion on Therapeutic Targets 2021; 25: 585-596
94380 Decorin-An Antagonist of TGF-β in Astrocytes of the Optic Nerve
Dillinger AE
International journal of molecular sciences 2021; 22:
95416 Agonist of growth hormone-releasing hormone enhances retinal ganglion cell protection induced by macrophages after optic nerve injury
Ng TK
Proceedings of the National Academy of Sciences of the United States of America 2021; 118:
94406 Carotenoids in the Management of Glaucoma: A Systematic Review of the Evidence
Gierhart DL
Nutrients 2021; 13:
94240 ATP and Adenosine in the Retina and Retinal Diseases
Tang Y
Frontiers in pharmacology 2021; 12: 654445
94673 Stimulation of α7 nAChR leads to regeneration of damaged neurons in adult mammalian retinal disease models
Sklar NC
Experimental Eye Research 2021; 210: 108717
94314 Agonistic autoantibodies against ß2-adrenergic receptor influence retinal microcirculation in glaucoma suspects and patients
Hosari S
PLoS ONE 2021; 16: e0249202
94764 Advances in the discovery of novel agents for the treatment of glaucoma
Nocentini A; Supuran CT
Expert Opinion on Drug Discovery 2021; 16: 1209-1225
94380 Decorin-An Antagonist of TGF-β in Astrocytes of the Optic Nerve
Ohlmann A
International journal of molecular sciences 2021; 22:
